For decades, the earliest detectable sign of Alzheimer's disease was considered to be amyloid plaque accumulation on a brain PET scan — a change that typically appears 10 to 20 years before symptoms begin. But a study published April 14, 2026 in Nature Communications by investigators at Harvard-affiliated Mass General Brigham has moved that frontier even earlier: a blood test measuring a protein called plasma phosphorylated tau 217 (pTau217) can detect changes consistent with early Alzheimer's disease progression before amyloid PET scans show anything abnormal.

This is not a marginal technical improvement. It represents a fundamental shift in the timeline of Alzheimer's detection — and consequently in the window for intervention, clinical trial enrollment, and preventive strategies.

"We used to think that PET scan detection was the earliest sign of Alzheimer's disease progression, revealing amyloid accumulation in the brain 10 to 20 years before symptoms appear," said lead author Dr. Hyun-Sik Yang, a Harvard Medical School assistant professor of neurology and neurologist at Brigham and Women's Hospital. "But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans."

What the Blood Test Measures and What the Study Found

pTau217 is a specific form of tau protein — the same protein that forms the neurofibrillary tangles that are one of the two pathological hallmarks of Alzheimer's disease, alongside amyloid plaques. Tau becomes hyperphosphorylated during the earliest stages of Alzheimer's pathology, and this modified form appears in the bloodstream at concentrations measurable through a standard blood draw.

The Mass General Brigham study used long-term longitudinal data from cognitively healthy older adults — individuals who showed no symptoms of dementia at the time of initial testing. Researchers found that higher pTau217 levels predicted faster buildup of Alzheimer's pathology on subsequent brain scans, even when initial scans appeared normal. Critically, increases in pTau217 frequently occurred before amyloid PET scans turned positive — confirming that the blood biomarker is detecting the earliest chemical signals of Alzheimer's development before structural brain changes become visible.

Equally important: participants with low pTau217 levels at the start of the study were very unlikely to accumulate significant amyloid on brain scans over many years of follow-up — meaning the test has strong negative predictive value. Clinicians can potentially reassure patients at low risk while focusing intervention resources on those at elevated risk.

The FDA Has Already Cleared a pTau217 Blood Test

This research is not purely theoretical. The U.S. Food and Drug Administration has already cleared the Lumipulse G pTau217 ratio blood test for use in aiding the diagnosis of Alzheimer's disease in adults aged 55 and older who are exhibiting symptoms of cognitive decline. The cleared test measures the ratio of pTau217 to beta-amyloid in blood plasma, with 91.7 percent of positive results confirmed by PET scan or CSF testing and 97.3 percent of negative results confirmed negative. This test can now reduce the need for costly amyloid PET scans — typically $3,000 or more — or invasive lumbar punctures.

More than 7 million Americans are currently living with Alzheimer's disease, and an estimated 6.9 million more are in the preclinical stage — meaning pathological changes have begun but symptoms have not yet appeared. For these individuals, a blood test that can identify elevated risk years before symptoms emerge creates a meaningful opportunity: enrollment in prevention trials, lifestyle interventions (aerobic exercise, cardiovascular risk management, cognitive engagement), and monitoring for the earliest possible intervention with emerging disease-modifying therapies such as lecanemab and donanemab.

Read more

Frequently Asked Questions

Q: What is the pTau217 blood test?

A: A blood test measuring plasma phosphorylated tau 217, a biomarker of early Alzheimer's pathology. Higher levels predict faster amyloid plaque accumulation and cognitive decline, even in people who appear cognitively healthy.

Q: Is this test available now?

A: The FDA has cleared the Lumipulse G pTau217 test for use in adults aged 55 and older who are showing symptoms of cognitive decline. Its use in cognitively healthy adults for screening is not yet FDA-cleared but is being actively researched.

Q: How does this compare to a PET scan?

A: The Harvard study confirms that pTau217 blood test changes occur before PET scan abnormalities become visible, making it an earlier and far less expensive detection method. It also does not involve radiation.

Q: What should someone do if they are concerned about Alzheimer's risk?

A: Talk to your primary care physician or neurologist. Discuss your family history, APOE4 genetic testing if appropriate, and whether a pTau217 test is indicated given your age and risk profile.